U.S. Defense Reports Immuron’s Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of travelers’ diarrhea
September 04, 2019 06:00 ET
|
Immuron Limited
Key Highlights: Major goal of study was to evaluate Travelan®’s ability to bind and react to a variety of infectious Vibrio cholera strains from Southeast Asia Pathogenic bacteria evaluated in study...
Immuron to Commence Non-Deal Investor Roadshow
August 16, 2019 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Prices Underwritten Public Offering of ADSs
July 17, 2019 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, July 17, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron to Host Investor Webinar on July 18 to Provide Update on Recent Developments
July 17, 2019 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, July 17, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced today that it will participate in an investor...
Immuron Announces Proposed Public Offering of ADSs
July 16, 2019 16:31 ET
|
Immuron Limited
MELBOURNE, Australia, July 16, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron North American revenue surges by 52% in FY19
July 16, 2019 06:00 ET
|
Immuron Limited
Key Highlights: Immuron FY19 revenue surged by 52% in North America, reaching $1.16M.In the USA, FY19 Travelan® sales exceeded the $1M AUD milestone for the first time and grew by +32% to $1.02M AUD....
Immuron Directors Increase Shareholdings in the Company
June 25, 2019 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, June 25, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company wishes to advise that two of its Directors, Mr Peter...
Immuron to Commence US Non-Deal Institutional Investor Roadshow
June 19, 2019 08:00 ET
|
Immuron Limited
MELBOURNE, Australia, June 19, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study
June 12, 2019 07:00 ET
|
Immuron Limited
Key Highlights: Travelan® shigellosis challenge studies in non-human primates successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals...
Immuron Announces the Closing of Public Offering of ADSs
May 30, 2019 08:00 ET
|
Immuron Limited
MELBOURNE, Australia, May 30, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin...